Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
1 to 25 of 805  Show
  1. 1
    "Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily."
    Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A.
    Biochemistry 30:3247-3255(1991) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ALLELE CYP2C19*1A).
    Category: Sequences.
    Tissue: Liver.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 4 other entries.

  2. 2
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 3 other entries.

  3. 3
    NIEHS SNPs program
    Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS LEU-19; ASP-92; ALA-122; HIS-144; ILE-331 AND CYS-410.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  4. 4
    "The DNA sequence and comparative analysis of human chromosome 10."
    Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., Taylor A., Battles J.
    , Bird C.P., Ainscough R., Almeida J.P., Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.
    Nature 429:375-381(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 1987 other entries.

  5. 5
    "Gene structure, upstream region and allelic variants of cyp2c19, the s-mephenytoin hydroxylase."
    de Morais S.M.F., Blaisdell J.A.
    Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-160 AND 274-490, VARIANT ILE-331.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  6. 6
    "Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation."
    Wrighton S.A., Stevens J.C., Becker G.W., VandenBranden M.
    Arch. Biochem. Biophys. 306:240-245(1993) [PubMed] [Europe PMC] [Abstract]
    Cited for: PROTEIN SEQUENCE OF 1-16.
    Category: Sequences.
    Tissue: Liver.
    Source: UniProtKB/Swiss-Prot (reviewed).
  7. 7
    "Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes."
    Miyazawa M., Shindo M., Shimada T.
    Drug Metab. Dispos. 30:602-607(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: CHARACTERIZATION.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 1 other entry.

  8. 8
    "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."
    Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., Zou H.
    J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
    Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
    Category: Sequences.
    Tissue: Liver.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 11200 other entries.

  9. 9
    "Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19."
    Reynald R.L., Sansen S., Stout C.D., Johnson E.F.
    J. Biol. Chem. 287:44581-44591(2012) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.87 ANGSTROMS) OF 23-489 IN COMPLEX WITH HEME AND SYNTHETIC INHIBITOR, COFACTOR.
    Category: Function, Interaction, Structure.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is mapped to 14 other entries.

  10. 10
    "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans."
    de Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A.
    J. Biol. Chem. 269:15419-15422(1994) [PubMed] [Europe PMC] [Abstract]
    Cited for: INVOLVEMENT IN POOR DRUG METABOLISM, IDENTIFICATION OF ALLELE CYP2C19*2A.
    Category: Pathology & Biotech.
    Source: UniProtKB/Swiss-Prot (reviewed).
  11. 11
    "Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese."
    De Morais S.M.F., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A.
    Mol. Pharmacol. 46:594-598(1994) [PubMed] [Europe PMC] [Abstract]
    Cited for: INVOLVEMENT IN POOR DRUG METABOLISM, IDENTIFICATION OF ALLELE CYP2C19*3A.
    Category: Pathology & Biotech.
    Source: UniProtKB/Swiss-Prot (reviewed).
  12. 12
    "Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele."
    Xiao Z.S., Goldstein J.A., Xie H.G., Blaisdell J., Wang W., Jiang C.H., Yan F.X., He N., Huang S.L., Xu Z.H., Zhou H.H.
    J. Pharmacol. Exp. Ther. 281:604-609(1997) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT TRP-433.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  13. 13
    "Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin."
    Ibeanu G.C., Goldstein J.A., Meyer U.A., Benhamou S., Bouchardy C., Dayer P., Ghanayem B.I., Blaisdell J.
    J. Pharmacol. Exp. Ther. 286:1490-1495(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANTS ASP-92 AND GLN-132.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  14. 14
    "An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians."
    Ibeanu G.C., Blaisdell J., Ghanayem B.I., Beyeler C., Benhamou S., Bouchardy C., Wilkinson G.R., Dayer P., Daly A.K., Goldstein J.A.
    Pharmacogenetics 8:129-135(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT TRP-433.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  15. 15
    "A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin."
    Ibeanu G.C., Blaisdell J., Ferguson R.J., Ghanayem B.I., Brosen K., Benhamou S., Bouchardy C., Wilkinson G.R., Dayer P., Goldstein J.A.
    J. Pharmacol. Exp. Ther. 290:635-640(1999) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT ARG-120.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  16. 16
    "Identification and functional characterization of new potentially defective alleles of human CYP2C19."
    Blaisdell J., Mohrenweiser H., Jackson J., Ferguson S., Coulter S., Chanas B., Xi T., Ghanayem B., Goldstein J.A.
    Pharmacogenetics 12:703-711(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANTS PRO-17; LEU-19; HIS-144; HIS-150; LEU-227 AND CYS-410.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  17. 17
    "A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation."
    Morita J., Kobayashi K., Wanibuchi A., Kimura M., Irie S., Ishizaki T., Chiba K.
    Drug Metab. Pharmacokinet. 19:236-238(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT CYS-442.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).
  18. 18
    "Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population."
    Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q., McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P.
    Pharmacogenomics 5:895-931(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANTS THR-74; HIS-144; LEU-168 AND ILE-331.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is cited by 10 other entries.

  19. 19
    Cited for: VARIANTS GLY-51; PRO-161; HIS-329 AND ILE-331.
    Category: Sequences.
    Source: UniProtKB/Swiss-Prot (reviewed).

    This publication is mapped to 2 other entries.

  20. 20
    "Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia."
    Roddam P.L., Rollinson S., Kane E., Roman E., Moorman A., Cartwright R., Morgan G.J.
    Pharmacogenetics 10:605-615(2000) [PubMed] [Europe PMC] [Abstract]
    Category: Pathology & Biotech.
    Annotation: Observational study of gene-disease association gene-gene interaction and gene-environment interaction. (HuGE Navigator)Imported, Not Associated with CANCER: leukemia, adult acute.Imported.
    Source: GAD:120898, GeneRIF:1557.

    This publication is mapped to 47 other entries.

  21. 21
    "Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia."
    Griese E.U., Ilett K.F., Kitteringham N.R., Eichelbaum M., Powell H., Spargo R.M., LeSouef P.N., Musk A.W., Minchin R.F.
    Pharmacogenetics 11:69-76(2001) [PubMed] [Europe PMC] [Abstract]
    Annotation: Observational study of genotype prevalence. (HuGE Navigator)Imported.
    Source: GeneRIF:1557.

    This publication is mapped to 47 other entries.

  22. 22
    "Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin."
    Furuta T., Shirai N., Takashima M., Xiao F., Hanai H., Sugimura H., Ohashi K., Ishizaki T., Kaneko E.
    Clin. Pharmacol. Ther. 69:158-168(2001) [PubMed] [Europe PMC] [Abstract]
    Annotation: Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)Imported.
    Source: GeneRIF:1557.

    This publication is mapped to 3 other entries.

  23. 23
    "Cytochrome P2 polymorphisms and susceptibility to scleroderma following exposure to organic solvents."
    Povey A., Guppy M.J., Wood M., Knight C., Black C.M., Silman A.J.
    Arthritis Rheum. 44:662-665(2001) [PubMed] [Europe PMC] [Abstract]
    Annotation: Observational study of gene-environment interaction. (HuGE Navigator)Imported.
    Source: GeneRIF:1557.

    This publication is mapped to 12 other entries.

  24. 24
    "Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients."
    Dandara C., Masimirembwa C.M., Magimba A., Sayi J., Kaaya S., Sommers D.K., Snyman J.R., Hasler J.A.
    Eur. J. Clin. Pharmacol. 57:11-17(2001) [PubMed] [Europe PMC] [Abstract]
    Annotation: Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)Imported.
    Source: GeneRIF:1557.

    This publication is mapped to 38 other entries.

  25. 25
    "CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects."
    Sakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., Hohda T., Sirasaka D., Tamura T., Tanigawara Y., Kasuga M., Okumura K.
    Pharm. Res. 18:721-727(2001) [PubMed] [Europe PMC] [Abstract]
    Annotation: Clinical trial of gene-disease association gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)Imported.
    Source: GeneRIF:1557.

    This publication is mapped to 3 other entries.

1 to 25 of 805  Show